A focused product with scalable commercial potential

Llusern’s primary commercial focus is rapid molecular UTI testing.

The Lodestar UTI testing system combines a portable analyser with recurring UTI test panel sales, creating a clear device-plus-consumables opportunity across professional human settings.

A device-plus-consumables model

Lodestar creates a practical commercial model built around the analyser and repeat use of UTI test panels.

The Lodestar DX analyser is a low cost testing platform. Busy settings can run multiple analysers in parallel.

The UTI test panels are the source of recurring revenue.

Lodestar allows professional users to run tests in settings where faster diagnosis can immediately impact patient pathways.

The Opportunity

Built around a clear diagnostic need

UTI testing is common, recurring and requires fast, accurate, professional  treatment decisions. Llusern is starting with this focused first use case because faster diagnostic information can support better-informed prescribing and more efficient care pathways.

  • Clear first product focus
  • High-volume diagnostic need
  • Rapid UTI testing
  • Near-patient molecular testing
  • Relevant across professional settings
Speak to the Team

Multiple professional settings

The Lodestar UTI testing system is designed for professional users in human settings. This means that Lodestar is relevant to a range of markets where faster UTI testing can support better decision-making.

Hospitals & near-patient settings

Potential to bring molecular testing closer to the clinical decision point in appropriate professional environments such as pre-operative assessments and obstetrics.

Specialist urology clinics

A focused professional healthcare setting where faster UTI testing can support better-informed decisions for patients with recurrent or complex symptoms.

Care homes & elderly care

A high-need setting where symptoms can be complex and faster diagnostic information can support more confident decisions.

Laboratories

A compact molecular testing option for settings where speed, size and workflow simplicity matter.

Community care

Faster diagnostic clarity during or close to consultation, supporting more informed prescribing decisions.

Distribution channels

Distributor-led growth potential can support access to multiple markets without requiring a direct sales model in every region.

Designed for practical adoption

Commercial potential depends on more than the test itself. It also depends on whether the product fits real-world settings.

Lodestar DX has been designed around portability, speed and simplicity, helping make molecular UTI testing more accessible for professional users beyond central laboratory environments.

  • Portable molecular testing system
  • Sample-to-result in less than 40 minutes
  • Requires only 10 μL of urine
  • No extraction step is required
  • Designed for near-patient use by professional users
  • UKCA marked

Active market entry with room to scale

The Lodestar UTI testing system is already being used in selected professional healthcare settings, with NHS evaluation activity supporting its real-world evidence base.

Llusern’s next stage of growth is focused on expanding professional adoption, building commercial partnerships and developing distributor-led growth opportunities.

  • Private healthcare adoption
  • Professional healthcare networks
  • Strategic commercial partnerships
  • NHS evaluation activity
  • Distributor-led growth

Starting with UTI. Built for broader diagnostic opportunity.

Llusern’s first focus is rapid molecular UTI testing. The wider ambition is to make treatment-directing diagnostics more accessible in professional settings where faster decisions matter.

Llusern is exploring menu extensions for its current panel, as well as applications within veterinary and industrial sectors – as well as other branches of medicine.

How Lodestar DX addresses this need

Testimonials

Lodestar DX represents an important step in making molecular UTI testing practical at the point where treatment decisions are made.
 
By bringing clearer diagnostic information closer to the patient, it can support faster, better-informed decisions in real-world professional settings.

Mr Bob Yang
Chief Medical Officer, Llusern Scientific

As a spinal injury patient, new symptoms feel overwhelming. Lodestar gave me instant peace of mind. I drove two hours to Reading just to avoid the usual three day wait for culture results. It is brilliant.

Luke
Patient

For months, my NHS results came back as ‘mixed growth’ or ‘no significant growth’, which basically left me with no treatment plan and I felt fobbed off; it was such a waste of everyone’s time.
 
The Lodestar machine identified the specific three bacteria immediately. I wish I’d come here sooner; it’s the first time I’ve had a definitive answer and I’ve felt empowered.

Hilary
Patient

News & Insights

    • Awards
    Insights

    Llusern bags a hat-trick at ICS 2026.

    Llusern is pleased to announce that three abstracts will be presented at the International Continence Society congress in Maastricht, 6-9 October 2026 focusing on the application of the Lodestar UTI testing system. Each abstract considers a different patient setting and demonstrates ways in which Lodestar…
    • Clinical Studies
    Insights

    Two abstracts published in The Journal of Urology.

    Llusern Scientific was pleased that two abstracts assessing the Lodestar UTI testing panel in clinical settings were published in the AUA's The Journal of Urology this month (May 2026). The researchers found that Lodestar DX "demonstrated strong performance as a rapid and reliable alternative to…
    • Appointments
    Insights

    Llusern announces changes to Exec team and new NED

    21st April 2026 Llusern Scientific Announces Changes To Executive Management Team And New NED Appointments made to advance the commercial launch of Llusern’s Lodestar UTI diagnostic system CARDIFF, United Kingdom, 21st April 2026 – Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of…
All News

Start a commercial conversation

Llusern has a clear first product, a focused diagnostic need and a device-plus-consumables opportunity with relevance across human and veterinary settings.

To learn more about the company, Lodestar and the opportunity ahead, speak to the Llusern team.